Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced positive results from a clinical study of its pipeline candidate, the antibody drug conjugate (ADC) 9MW2821, which targets Nectin-4. The data, highlighting the potential of 9MW2821 in treating cervical cancer, is set to be presented at the 55th annual meeting of the Society of Gynecologic Oncology (SGO). Previously, 9MW2821 has shown promising results in the treatment of urothelial carcinoma.
Approximately 90% of cervical cancer patients express Nectin-4, with about 68% exhibiting intense 3+ tumor cell staining for the antigen. The clinical data has demonstrated that among 37 patients with recurrent or metastatic cervical cancer expressing Nectin-4 treated with 9MW2821, the objective response rate (ORR) and disease control rate (DCR) were 40.54% and 89.19%, respectively. Notably, in the subset of 26 patients with Nectin-4 3+ disease, the ORR and DCR were as high as 50% and 92.31%, respectively. Furthermore, in 21 patients who had failed platinum-based doublet chemotherapy and immune checkpoint inhibitor treatment, the ORR and DCR were 38.1% and 85.71%, respectively.- Flcube.com
